적극ive efforts under the Foods with Function Claims system
First written in FY2016-Q3. 25 of 29 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2024.
1 other company's latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「The main functional ingredients include PharmaGABA, which supports functional claims for six functions: “stress relief,” “reduced fatigue,” “improved blood pressure,” “improved sleep quality,” “improved skin elasticity” and “improved cognitive function,”」
For PharmaGABA, the business is explicitly described as supporting functional claims for six functions, including skin elasticity and cognitive function in addition to the existing functions. - FY2024-Q3AdvancedAnnual report
「In particular, in the domestic market, GABA notifications under the Foods with Function Claims system totaled 1,139 as of 15 May 2024, compared with 891 in the same period of the previous year, maintaining its leading adoption record.」
GABA notifications increased from 891 in the same period of the previous year to 1,139, maintaining the leading adoption record. - FY2024-Q2AdvancedAnnual report
「In particular, in the domestic market, GABA notifications under the Foods with Function Claims system totaled 1,086 as of the end of February 2024, compared with 824 in the same period of the previous year, maintaining its leading adoption record. GABA’s market expansion has continued, including its adoption in sleep-care products from a major beverage manufacturer.」
GABA notifications increased from 824 in the same period of the previous year to 1,086, maintaining the leading adoption record. Adoption in sleep-care products from a major beverage manufacturer was also disclosed, indicating expansion into new applications. - FY2024-Q1AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 1,018 as of 31 October 2023, compared with 750 in the same period of the previous year, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 750 in the same period of the previous year to 1,018, maintaining the leading adoption record. - FY2023AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 999 as of 21 September 2023, compared with 716 in the previous period, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 716 in the previous period to 999, maintaining the leading adoption record. - FY2023-Q2AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 824 as of the end of January 2023, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 750 previously to 824, maintaining the leading adoption record as of the end of January 2023. - FY2023-Q1AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 750 as of the end of October 2022, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 716 previously to 750, maintaining the leading adoption record. - FY2022AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 716 as of 31 July 2022, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 685 to 716, maintaining the leading adoption record. - FY2022-Q3AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system totaled 685 as of 17 May 2022, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 625 previously to 685, maintaining the leading adoption record under the system. - FY2022-Q2AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 625 as of the end of January 2022, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 568 previously to 625, maintaining the leading adoption record. Food manufacturers have also continued to expand their adoption. - FY2022-Q1AdvancedAnnual report
「In the domestic market, GABA notifications under the Foods with Function Claims system totaled 568 as of the end of October 2021, maintaining its leading adoption record. Food manufacturers have continued to expand their adoption of GABA.」
GABA notifications increased from 479 at the end of April 2021 to 568, maintaining the leading adoption record. Food manufacturers have also continued to expand their adoption. - FY2021AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system totaled 503 as of the end of June 2021, maintaining its leading adoption record. The expansion of GABA adoption by food manufacturers has led to increased orders for the Company’s PharmaGABA®, which holds the leading market share.」
GABA notifications increased from 479 at the end of April 2021 to 503, maintaining the leading adoption record. The relationship between increased adoption by food manufacturers and increased orders for PharmaGABA was also reiterated. - FY2021-Q3AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system totaled 479 as of the end of April 2021, maintaining its leading adoption record. The expansion of GABA adoption by food manufacturers has led to increased orders for the Company’s PharmaGABA®, which holds the leading market share.」
GABA notifications totaled 479 as of the end of April 2021, up from 434 previously. The leading adoption record was maintained, and the disclosure states that increased adoption by food manufacturers has led to increased orders. - FY2021-Q2AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system totaled 434 as of the end of January 2021, maintaining its leading adoption record. The expansion of GABA adoption by food manufacturers has led to increased orders for the Company’s PharmaGABA®, which holds the leading market share.」
GABA notifications increased to 434 as of the end of January 2021, maintaining the leading adoption record. The disclosure also describes the relationship between increased adoption by food manufacturers and increased orders for PharmaGABA. - FY2021-Q1AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system, which began in 2015, totaled 412 as of the end of October 2020, maintaining its leading adoption record. Several major beverage manufacturers are planning to sell foods with functional claims containing PharmaGABA® that promote the maintenance and improvement of cognitive function and stress relief, which is expected to contribute to sales from the cumulative second-quarter consolidated period onward.」
GABA notifications totaled 412 as of the end of October 2020, maintaining the leading position. Plans to sell products from major beverage manufacturers promoting cognitive function and stress relief were also disclosed, indicating progress in regulatory compliance and expansion into new applications. - FY2020-Q3AdvancedAnnual report
「GABA notifications under the Foods with Function Claims system, which began in 2015, totaled 336 as of the end of April 2020, maintaining its leading adoption record,」
GABA notifications for foods with functional claims totaled 336 as of the end of April 2020, maintaining the leading adoption record. - FY2020-Q2AdvancedAnnual report
「As a result, GABA notifications under the Foods with Function Claims system, which began in 2015, totaled 318 as of the end of January 2020, giving it the highest adoption record, and increased sharply during the cumulative second-quarter consolidated period.」
GABA notifications totaled 318 as of the end of January 2020, rising from the previous second-place position to first place. - FY2020-Q1AdvancedAnnual report
「The number of notifications under the Foods with Function Claims system, which began in 2015, reached 2,559 as of the end of November 2019, and awareness of the system has steadily spread. Of these, 290 notifications concerned GABA, giving it the second-highest adoption record among all items.」
The number of notifications for the system as a whole rose to 2,559, while GABA notifications rose to 290, from more than 2,200 and 253, respectively, in the previous disclosure. Its second-highest adoption record among all items has also continued. - FY2019AdvancedAnnual report
「The number of notifications under the Foods with Function Claims system, which began in 2015, exceeded 2,200 as of the end of July 2019, and awareness of the system has steadily spread. Of these, 253 notifications concerned GABA, giving it the second-highest adoption record among all items.」
The number of notifications for the system as a whole exceeded 2,200, while GABA notifications rose to 253, from 1,946 and 228, respectively, in the previous disclosure. Its second-place adoption record has also continued. - FY2019-Q3AdvancedAnnual report
「The number of notifications under the Foods with Function Claims system, which began in April 2015, had steadily increased to 1,946 as of the end of April 2019, and awareness of the system had spread. Of these, 228 notifications concerned GABA, giving it the second-highest adoption record among all items.」
The number of notifications for the system as a whole rose to 1,946, while GABA notifications rose to 228, from 1,747 and 199, respectively, previously. Its second-highest adoption record among all items has also continued. - FY2019-Q2AdvancedAnnual report
「The number of notifications under the Foods with Function Claims system, which began in April 2015, had steadily increased to 1,747 as of the end of January 2019, and awareness of the system had spread. Of these, 199 notifications concerned GABA, giving it the second-highest adoption record among all items.」
The number of notifications for the system as a whole rose to 1,747, while GABA notifications rose to 199, from more than 1,600 and 191, respectively, previously. Its second-highest adoption record among all items has also continued. - FY2019-Q1AdvancedAnnual report
「The number of notifications under the Foods with Function Claims system, which began in April 2015, exceeded 1,600 as of the end of October 2018, and awareness of the system has steadily spread. Of these, 191 notifications concerned GABA, giving it the second-highest adoption record among all items.」
The scale and ranking of regulatory compliance are shown in specific figures: more than 1,600 notifications for the system as a whole, and 191 GABA notifications, ranking second among all items. - FY2018-Q3RestatedAnnual report
「In the domestic business, sales have remained firm as a result of increases in notifications and sales of foods with functional claims containing GABA.」
The company continues to expand notifications and sales of foods with functional claims containing GABA. No new progress exceeding the previously reported four functions or ranking by accepted notifications is described. - FY2018-Q2RestatedAnnual report
「In the domestic business, sales have remained firm as a result of increases in notifications and sales of foods with functional claims containing GABA.」
The company has reconfirmed the increase in notifications and sales of foods with functional claims containing GABA, as well as firm sales. No new achievements exceeding the previously reported acceptance of notifications for four functions or the second-place ranking in accepted notifications are described. - FY2018-Q1AdvancedAnnual report
「The number of functional claims notifications for GABA-containing products addressing “stress,” “fatigue,” “blood pressure” and “sleep” has steadily increased, with accepted notifications ranking second among all functional ingredients, and domestic sales have increased substantially.」
The number of functional claims notifications for GABA-containing products has steadily increased, and the disclosure describes both the acceptance record for the four functions and the second-place ranking among all functional ingredients, as well as a substantial increase in domestic sales. - FY2017-Q3AdvancedAnnual report
「Manufacturers have submitted functional claims notifications for “stress,” “fatigue,” “blood pressure” and “sleep” products containing “GABA,” and the number of accepted notifications ranks second among all functional ingredients.」
In addition to acceptance of notifications for the four existing functions, the number of accepted functional claims notifications for GABA ranks second among all functional ingredients, demonstrating concrete progress in regulatory compliance. - FY2017-Q2AdvancedAnnual report
「In addition to “stress,” “fatigue” and “blood pressure,” a notification for a new function claim relating to “sleep” has been accepted for GABA.」
Regarding “sleep,” which was described as being under development in the previous quarter, progress has been made through acceptance of the functional claims notification. - FY2017-Q1RaisedAnnual report
「Since this autumn, Ezaki Glico Co.,Ltd. has begun selling “Mental Balance Chocolate GABA” as a Food with Function Claims, resulting in strong sales to the company. Foods with Function Claims containing GABA have also been launched sequentially by other manufacturers, broadening awareness. Function claims for GABA relating to “stress,” “fatigue” and “blood pressure” have been accepted, and the Group is now pursuing a new function claim relating to “sleep.”」
In addition to the existing three functions, the Company has begun pursuing “sleep,” and the scope of its initiatives under the system is expanding as products are launched by multiple manufacturers. - FY2016-Q3First statedAnnual report
「In Japan, we have been actively pursuing initiatives under the Foods with Function Claims system, which began last April, and have received inquiries from many food and beverage manufacturers. As a result, notifications of function claims relating to “stress,” “fatigue” and “blood pressure” have been accepted for multiple manufacturers, and product launches will begin sequentially from the end of the current fiscal year through the next fiscal year.」
The Company is advancing the system as a means of supporting sales and commercialization, with notifications accepted for multiple manufacturers and product launches scheduled.